Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | TSHR | P16473 | 2/20 | 0.63 |
| ▸ | CASP1 | P29466 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | GRIK1 | P39086 | 6/20 | 0.53 |
| ▸ | MYC | P01106 | 2/20 | 0.49 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methacrylic Acid SCHEMBL27562840 | 0.88 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL275101 | 0.83 | ALDH1A1 (0.63) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL1626671 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL14439664 | 0.81 | SMN1; SMN2 (0.45) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL1196041 | 0.81 | KDM4E (0.50) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| Fenamic Acid SCHEMBL7813058 | 0.80 | FABP4 (0.60) | GRIK1KDM4EMEN1KMT2A | |
| SCHEMBL1000440 | 0.79 | ALDH1A1 (0.71) | SMN1; SMN2TSHRCASP1ALDH1A1TP53 | |
| SCHEMBL153284 | 0.79 | MAPT (0.54) | SMN1; SMN2ALDH1A1TP53GRIK1KDM4E | |
| SCHEMBL13485808 | 0.78 | HDAC8 (0.49) | SMN1; SMN2TSHRCASP1ALDH1A1GRIK1 | |
| SCHEMBL588405 | 0.77 | PTPN1 (0.48) | SMN1; SMN2TSHRCASP1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 281 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472313-B1 | Process for synthesizing trifluoroketones | GRAPHENE 3D LAB INC. (US) | 2019-11-12 | — | — | US | claimed |
| EP-4712969-A1 | CYCLIN INHIBITORS | Circle Pharma, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-08-05 | — | — | US | disclosed |
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-06-19 | — | — | US | disclosed |
| CN-120081802-A | Heterocyclic substituted benzamide derivative and application thereof | 南华大学附属第一医院 | 2025-06-03 | — | — | CN | disclosed |
| CN-119977947-A | PRMT5 inhibitor, pharmaceutical composition thereof and application of PRMT5 inhibitor in medicines | 广东东阳光药业股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| US-12274163-B2 | Compound for organic electrical element, organic electrical element using same and electronic device thereof | DUK SAN NEOLUX CO., LTD. (KR) | 2025-04-08 | — | — | US | disclosed |
| EP-4476207-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-20240408169-A1 | CYCLIN INHIBITORS | CIRCLE PHARMA, INC. | 2024-12-12 | — | — | US | disclosed |
| US-4118572-A | CNS DEPRESSANTS, NEUROLEPTIC AGENTS, SCHIZOPHRENIA, TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1978-10-03 | — | — | US | disclosed |
| US-4105664-A | Dibenz[b,f]oxepin derivatives | HOFFMANN-LA ROCHE INC. (US) | 1978-08-08 | — | — | US | disclosed |
| US-4100173-A | DEPRESSANTS, SCHIZOPHRENIA, TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1978-07-11 | — | — | US | disclosed |
| US-4091023-A | ANTISCHIZOPHRENIA AGENTS, TRANQUILIZERS | HOFFMANN-LA ROCHE INC. (US) | 1978-05-23 | — | — | US | disclosed |
| US-4086350-A | FLUORO, CHLORO AND CYANO SUBSTITUTED 4-(9-XANTHENYLIDENE, 9-THIOXANTHENYLIDENE OR 11(6H)-DIBENZO(B,E)OXEPINYLIDENE)-1-METHYL-PIPERIDINES | SMITHKLINE CORPORATION (US) | 1978-04-25 | — | — | US | disclosed |
| US-4044010-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-08-23 | — | — | US | disclosed |
| US-4032525-A | CNS DEPRESSANTS, NEUROLEPTICS | HOFFMANN-LA ROCHE INC. (US) | 1977-06-28 | — | — | US | disclosed |
| US-4011222-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1977-03-08 | — | — | US | disclosed |
| US-3966737-A | NEUROLEPTIC | HOFFMANN-LA ROCHE INC. (US) | 1976-06-29 | — | — | US | disclosed |
| US-3954764-A | NEUROLEPTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12274163-B2 | Compound for organic electrical element, organic electrical element using same and electronic device thereof | PIEZO1, ASIC1, TMEM109 | SMN1; SMN2 695/4885TSHR 4643/4885CASP1 204/4885 |
| US-20250195483-A1 | SPIRO PIPERIDINE DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, SAAL1 | SMN1; SMN2 527/4885TSHR 4177/4885CASP1 1297/4885 |
| US-20240408169-A1 | CYCLIN INHIBITORS | CCNI, CDK2, CDK1 | SMN1; SMN2 3067/4885TSHR 3858/4885CASP1 2908/4885 |
| US-12378254-B2 | Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators | HCRTR2, HCRTR1, OXTR | SMN1; SMN2 3009/4885TSHR 344/4885CASP1 4136/4885 |
| US-10472313-B1 | Process for synthesizing trifluoroketones | FRK, PFKFB2, PFKFB1 | SMN1; SMN2 761/4885TSHR 2606/4885CASP1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.